



IBA reduces energy-related costs of proton therapy

Breakthrough in proton accelerator's technology reduces isochronous cyclotron power consumption by 30%

Louvain-la-Neuve, May 21, 2015 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer announced today the release of an exclusive feature that reduces the power consumption of IBA proton therapy 230 MeV isochronous cyclotron (C230) by >30%. This unique feature helps reduce the overall cost of proton therapy, making it ever more accessible to patients worldwide.

First measurements at the Institut Curie's Orsay Proton Therapy Center (France) show that the power consumption of the cyclotron has been lowered by an average of 30% over a month's period.

"This is significant" said Frédéric Genin, Executive Vice President, Product Development Management at IBA "this feature is a great accomplishment. It dramatically reduces the operation costs of proton therapy centers hence making the treatment more affordable and the technology more accessible. It is only a first step as additional energy saving features are being tested to further reduce energy-related costs."

Weisheng Duan, Product Manager at IBA added: *"This new feature can be retrofitted to all existing systems.. It addresses a major area of concern for our customers as the prices of energy are generally going up. It will help them to significantly reduce their energy bill while making a positive impact on the environment."*

The IBA Isochronous Cyclotron (C230) enables physicians to deliver the highest quality clinical proton beam that is both highly precise and symmetrical with a very stable energy of 230MeV and a high yield. It benefits from the experience gained over 25 years at 16 operating centers. This new generation has been designed with clinical operations in mind. It offers automatic operations, remote monitoring and predictive maintenance programs. IBA provides its customers the highest uptime in the radiation therapy market to ensure maximum system availability for cancer patient treatment.

- END -

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. www.iba-protontherapy.com

Today, more than half of proton therapy clinical facilities worldwide are IBA systems. This includes 18 proton therapy centers in operation and 16 additional centers under development. Over 25,000 patients have been treated on IBA equipment – more than on all major competitive installations combined.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy



solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager Proton Therapy
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal
+44 (0) 207 920 2333
IBA@consilium-comms.com